OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in antibody discovery that came to market via a business combination with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. OmniAb was carved out of Ligand Pharmaceuticals as part of the de-SPAC transaction, which closed in October 2022; this 10-Q, filed August 12, 2022, covers a period before the merger's completion. The company operates in the life sciences sector, providing its antibody discovery platform to pharmaceutical and biotech partners developing next-generation therapeutic candidates. For complete SPAC filing histories, sponsor profiles, and deal analytics on OABI and hundreds of other transactions, sign up for full data on SpacDesk.